Iavor K. Vladimirov

Dr. Iavor K. Vladimirov


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2017 in Reproductive Medicine and Biology
Verified
Journal Article
Open access
PDF file
IVIavor K. Vladimirov
Iavor K. Vladimirov
DTDesislava Tacheva
Desislava Tacheva
ADAntonio Diez
Antonio Diez
Background: To create hypothesis, which can give a logical explanation related to the benefits of freezing/thawing embryos. Cryopreservation is not only a technology used for storing embryos, but also a method of embryo treatment that can potentially improve the success rate in infertile couples.Methods: From the analysis of multiple results in assisted reproductive technology, which have no satisfactory explanation to date, we found evidence to support a ‘therapeutic’ effect of the freezing/thawing of embryos on the process of recovery of the embryo and its subsequent implantation.Results: Freezing/thawing is a way to activate the endogenous survival and repair responses in preimplantation embryos. Several molecular mechanisms can explain the higher success rate of ET using thawed embryos compared to fresh ET in women of advanced reproductive age, the higher miscarriage rate in cases of thawed blastocyst ET compared to thawed ET at early cleavage embryo, and the higher perinatal parameters of born children after thawed ET. Embryo thawing induces a stress. Controlled stress is not necessarily detrimental, because it generates a phenomenon that is counteracted by several known biological responses aimed to repair mitochondrial damage of membrane and protein misfolding. The term for favorable biological responses to low exposures to stress is called hormesis.Conclusions: This thesis will summarize the role of cryopreservation in the activation of a hormetic response, preserving the mitochondrial function, improving survival, and having an impact on the process of implantation, miscarriage, and the development of pregnancy.

28 August 2019
Verified
Book Chapter
Open access
PDF file
IVIavor K. Vladimirov
Iavor K. Vladimirov
DTDesislava Tacheva
Desislava Tacheva
VDVladislav Dobrinov
Vladislav Dobrinov
Embryo freezing technologies have widely been used in human IVF practice and in animal industry. In this chapter, we will review the development of embryo freezing technology and the application of the method, which will concentrate on discussion of the arguments in favor of and against freezing, as well as the latest results of success rates, comparing them with the other basic assisted reproductive technologies methods. Then, we will present our viewpoint for the future application of embryo freezing methods and their place in reproductive medicine. The analysis of facts and suggestions should enable researchers to rethink the position of cryobiology in reproductive medicine. It should be considered that the method of cryopreservation is not only a technology for storing embryos but also a method of embryo treatment that can potentially improve the success rates in infertile couples. There is also a theory that describes the “treatment” effect of freezing an embryo, which may explain the higher success rates of frozen embryo transfer (FET) compared to fresh embryo transfer (ET). The authors of the “Theory about the Embryo-Cryo treatment” believe that freezing and thawing could activate endogenous survival and repair mechanisms in preimplantation embryos.

10 May 2023
Verified
Book Chapter
Open access
PDF file
IVIavor K. Vladimirov
Iavor K. Vladimirov
MVMartin Vladimirov
Martin Vladimirov
Open access peer-reviewed chapter

27 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
IVIavor K. Vladimirov
Iavor K. Vladimirov
DTDesislava K. Tacheva
Desislava K. Tacheva
EGEvan Gatev
Evan Gatev
MRMagdalena Rangelova
Magdalena Rangelova
IVIavor K. Vladimirov
Iavor K. Vladimirov
Purpose: This study aims to establish the viability of monitoring an appropriate and safe ovarian stimulation without the use of ultrasound and serum hormone testing. Method: As a primary marker for monitoring of the ovarian response, we used urinary estrone-3-glucuronide (E1-3G) growth rate, which was self-measured by patients daily at home, with a portable analyzer, during the stimulation. For an adequate ovarian response, an average daily rate of increase of E1-3G was estimated to be within 25 - 77%. Ovulation trigger day was determined based on the length of the menstrual cycle. The study included 24 women. Inclusion criteria were age < 41 years and AMH >1 ng/mL. A progestin-primed ovarian stimulation protocol (PPOS) with fixed doses of gonadotropins was used. Results: The average female age was 32,9 years (±4.4), BMI 22,7 kg/m2 (±4,3), AMH 3,7 ng/ml (±2,6), stimulation days 10,6 (±1,1), collected oocytes 12,5 (±8,5), MII oocytes 10,6 (±7,8), fertilization rate 83,6% (±22,5), blastocyst 66,4% (±28,6), good quality blastocysts 31,6% (±16,9). Absence of oocyte aspiration was found in one of the cases. There were no cases of OHSS and ovarian stimulation cancellation. Conclusion: This is the first pilot study to successfully apply a new markers for ovarian stimulation monitoring.

14 July 2026
Verified
Book Chapter
Open access
PDF file
VKVesela Ivanova Karamisheva
Vesela Ivanova Karamisheva
MVMartin Vladimirov
Martin Vladimirov
DKDaria Zhivkova Koleva
Daria Zhivkova Koleva
AKAnatoli Kolev
Anatoli Kolev
BKBozhidar Vladimirov Karamishev
Bozhidar Vladimirov Karamishev
IVIavor K. Vladimirov
Iavor K. Vladimirov
Endometriosis (EM) is a chronic, estrogen-dependent, inflammatory disease characterized by the presence of endometrial-like tissue outside the uterus. It is estimated that EM occurs in approximately 10% of women of the reproductive age and is associated with severe morbidity in the form of chronic pelvic pain and subfertility. Diagnosis is challenging due to nonspecific symptoms, long diagnosis-to-treatment times (4–11 years), the inability of imaging techniques to accurately locate superficial lesions, and the lack of validated noninvasive biomarkers. The latest European Society of Human Reproduction and Embryology (ESHRE) and American College of Obstetricians and Gynecologists (ACOG) guidelines no longer consider laparoscopy as the reference standard test. Presently, the management of EM is focused on symptom control using hormones (such as combined oral contraceptives, progestins, and gonadotropin-releasing hormone analogs) and surgery in non-responders or for fertility preservation. However, EM is highly recurrent, with recurrence rates of up to 50% at five years after treatment, associated with numerous side effects and limited improvement in fertility preservation rates. Precision medicine for EM will require the identification of multiomic biomarkers of the disease to develop non-invasive approaches for the diagnosis and management of EM using artificial intelligence-based imaging technologies and novel immunomodulatory drugs.